Evidence map›Paper›PMID 41929163›Full record

ArticlebioRxiv : the preprint server for biology2026

EvoMut: A Computational Framework for Engineering Oxidative Stability in Proteins.

Seyed Shahriar Arab, Nathan E Lewis

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Seyed Shahriar ArabCenter for Molecular Medicine, University of Georgia, Athens, GA 30602, United States.ORCID 0000-0002-2739-1617
Nathan E LewisCenter for Molecular Medicine, University of Georgia, Athens, GA 30602, United States.ORCID 0000-0001-7700-3654

Funding

Unraveling the mammalian secretory pathway through systems biology and algorithm developmentR35GM119850 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEWIS, NATHAN ENOCH · 2016 to 2025
$4.3M
Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsinR41HL164260 · NHLBI · NEUIMMUNE BIOLOGICS, INC. · PI LEWIS, NATHAN ENOCH · 2022 to 2022
$274k
NHLBI NIH HHS R41 HL164260NIGMS NIH HHS R35 GM119850
6 · The paper itself

Abstract

Amino acid oxidation is a major cause of protein instability and loss of function in therapeutic and industrial settings. Although methionine, cysteine, tyrosine, and tryptophan residues are widely recognized as oxidation-prone, only a subset of such residues are dominant functional hotspots, and not all are suitable targets for mutation. Identifying these vulnerable yet engineerable sites remains a major challenge. Here, we present EvoMut, a residue-level analytical framework for evaluating both oxidative vulnerability and mutation feasibility. EvoMut estimates oxidation risk by integrating structural features, local functional context, intrinsic chemical susceptibility, and evolutionary conservation. A central feature of the framework is the explicit separation of oxidation risk from mutation feasibility: candidate substitutions are evaluated only after high-risk residues are identified and ranked by evolutionary substitution patterns. Application of EvoMut to multiple proteins, and evaluation with experimental data, showed that oxidation-prone residues differ markedly in their engineering potential. EvoMut distinguishes residues that are both oxidationsensitive and evolutionarily permissive from those that are chemically vulnerable but functionally constrained. By providing residue-level mechanistic insight, EvoMut offers a practical framework for the rational design of oxidation-resistant proteins. EvoMut is freely available as a web server at https://evomut.org.

Indexed as

evolutionary conservationoxidative hotspot predictionoxidative stability engineeringprotein engineeringprotein oxidationstructural bioinformatics

Identifiers

PMID41929163
PMCPMC13041978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.